Oruka Therapeutics $500 million at-the-market offering
We advised Oruka on the offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
AbbVie $10 billion senior notes offering
We advised the underwriters on the offering
Illumina $300 million notes offering
We advised the underwriters on the offering
athenahealth $500 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Inotiv emerges from chapter 11
We advised an ad hoc group of first-lien lenders in connection with Inotiv’s chapter 11 proceedings
REGENXBIO $115 million equity offering
We advised the joint book-running managers and underwriters on the offering
Ascentage Pharma $200 million at-the-market offering
We advised the sales agents on the offering
GenFleet Therapeutics HK$471.8 million placement of new H shares
We advised GenFleet Therapeutics on the placement
Alebund Pharmaceuticals HK$1.28 billion IPO
We advised Alebund Pharmaceuticals on its IPO and HKEX listing
Talawar Therapeutics $225 million PIPE financing and de-SPAC transaction
We advised the placement agents on the transaction